Differentiated Thyroid Cancer in Navarra Spain: Historic Cohort Results 1987–2003Report as inadecuate




Differentiated Thyroid Cancer in Navarra Spain: Historic Cohort Results 1987–2003 - Download this document for free, or read online. Document in PDF available to download.

ISRN OncologyVolume 2011 2011, Article ID 560503, 8 pages

Research Article

Department of Surgery, Complejo Hospitalario de Navarra, Irunlarrea street 3, 31008 Pamplona, Spain

Department of Pathology, Complejo Hospitalario de Navarra, Irunlarrea street 3, 31008 Pamplona, Spain

Department of Preventive Medicine, Complejo Hospitalario de Navarra, Irunlarrea street 3, 31008 Pamplona, Spain

Department of Endocrinology, Complejo Hospitalario de Navarra, Irunlarrea street 3, 31008 Pamplona, Spain

Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias, Celestino Villamil Street s-n, 33006 Oviedo, Spain

Received 17 May 2011; Accepted 14 June 2011

Academic Editors: E. Boven and C. N. Qian

Copyright © 2011 María Pilar Salvador Egea et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. Navarra has the highest incidence of differentiated thyroid cancer in Spain. The aim of this study was to review its management carried out by the Navarra-s multidisciplinary Thyroid Disease Unit, from 1987 to 2003. Material and Methods. 325 patients were studied to find the incidence, prevalence, and prognostic factors. Statistical analysis comprised univariate and multivariate Cox proportional hazards regression models for survival and tumor recurrence. Results. The average annual incidence was 3.6 per 100,000 inhabitants, with a final prevalence of 82.4 per 100,000. Regarding survival and recurrence, statistical significance was observed for stage IV, follicular carcinoma, capsular and prethyroid muscles invasion, and T4 group. Only survival was related to tumour size larger than 40 mm. Only recurrence was related to lymph node metastases and radioiodine dose higher than 100 mCi. Conclusions. Attendance of patients in a functional unit setting has allowed us to classify them into three risk groups.





Author: María Pilar Salvador Egea, Ana Aranzazu Echegoyen Silanes, Eduardo Layana Echezuri, Emma Anda Apiñariz, Ana Puras Gil, Edel

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents